These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 526527)
1. Designing and analyzing clinical trials which allow institutions to randomize patients to a subset of the treatments under study. Schoenfeld DA; Gelber RD Biometrics; 1979 Dec; 35(4):825-9. PubMed ID: 526527 [TBL] [Abstract][Full Text] [Related]
2. On design considerations and randomization-based inference for community intervention trials. Gail MH; Mark SD; Carroll RJ; Green SB; Pee D Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140 [TBL] [Abstract][Full Text] [Related]
3. Sample size for two-stage studies with maintenance therapy. Feng W; Wahed AS Stat Med; 2009 Jul; 28(15):2028-41. PubMed ID: 19382105 [TBL] [Abstract][Full Text] [Related]
4. Designing for cancer clinical trials: selection of prognostic factors. Brown BW Cancer Treat Rep; 1980; 64(2-3):499-502. PubMed ID: 7407790 [TBL] [Abstract][Full Text] [Related]
8. Statistical inference and the design of clinical trials. Berry DA Biomedicine; 1980 Feb; 32(1):4-7. PubMed ID: 7370380 [TBL] [Abstract][Full Text] [Related]
9. Investigating maximum power losses in survival studies with nonstratified randomization. Palta M Biometrics; 1985 Jun; 41(2):497-504. PubMed ID: 4027324 [TBL] [Abstract][Full Text] [Related]
10. [Statistical methods in the evaluation of the therapeutic efficacy--their problems and solutions]. Tominaga S Gan To Kagaku Ryoho; 1982 Nov; 9(11):1873-81. PubMed ID: 6764094 [TBL] [Abstract][Full Text] [Related]
12. Patient heterogeneity in clinical trials. Simon R Cancer Treat Rep; 1980; 64(2-3):405-10. PubMed ID: 7407777 [TBL] [Abstract][Full Text] [Related]
13. [Use of prognostic knowledge in the planning and analysis of randomized therapeutic trials]. Byar D; Chastang C Bull Cancer; 1987; 74(2):177-84. PubMed ID: 3607300 [TBL] [Abstract][Full Text] [Related]
14. [Application of sequential methods in randomized clinical trials with censored response criteria]. Benichou J; Chastang C Rev Epidemiol Sante Publique; 1986; 34(3):196-208. PubMed ID: 3786877 [TBL] [Abstract][Full Text] [Related]
15. Optimal design of clinical trials comparing several treatments with a control. Marschner IC Pharm Stat; 2007; 6(1):23-33. PubMed ID: 17323312 [TBL] [Abstract][Full Text] [Related]
17. Consultants' forum: should post hoc sample size calculations be done? Walters SJ Pharm Stat; 2009; 8(2):163-9. PubMed ID: 18416448 [TBL] [Abstract][Full Text] [Related]
18. Sample size determination for comparing several survival curves with unequal allocations. Halabi S; Singh B Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409 [TBL] [Abstract][Full Text] [Related]
19. Effect of continuous versus dichotomous outcome variables on study power when sample sizes of orthopaedic randomized trials are small. Bhandari M; Lochner H; Tornetta P Arch Orthop Trauma Surg; 2002 Mar; 122(2):96-8. PubMed ID: 11880910 [TBL] [Abstract][Full Text] [Related]
20. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Freidlin B; Simon R Clin Cancer Res; 2005 Nov; 11(21):7872-8. PubMed ID: 16278411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]